Paolo Ascierto, MD, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy, discusses primary results from the phase 2 NEO-TIM trial which sought to determine the optimal sequencing of vemurafenib, cobimetinib, and atezolizumab among patients with patients with high-risk melanoma.
2024
Tumor-infiltrating lymphocyte therapy marks a milestone in cancer treatment, researchers say
The recent U.S. Food and Drug Administration approval of lifileucel, the first commercial tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma, marks a significant breakthrough in cancer therapy. In a new commentary published in Cancer Cell, Moffitt Cancer Center scientists provide a comprehensive overview of the therapy’s development and highlight its transformative potential.
Presurgical Targeted Therapy, Immunotherapy Show Responses in Melanoma
Researchers have found that among patients with certain melanoma, presurgical targeted therapy and immunotherapy can result in better pathologic response.
Some melanoma cancer cells may punch their way through the body
Imagine tiny fists punching their way through your body.